NCT02601157: HOST-IDEA

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial

Completed Phase 4 Last updated 10 January 2023

What this trial tests

Phase 4 trial testing 3-months DAPT in Stable Angina in 2,173 participants. Completed in 14 August 2022.

Timeline

18 January 2016

Primary endpoint
14 August 2021

14 August 2022

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2,173
Start date	18 January 2016
Primary completion	14 August 2021
Estimated completion	14 August 2022
Sites	12 locations across South Korea

Drugs / interventions tested

• 3-months DAPT
• 1-year DAPT — full drug profile →

Conditions studied

• Stable Angina — all drugs for Stable Angina →
• Unstable Angina — all drugs for Unstable Angina →
• Non-ST Segment Elevation Myocardial Infarction — all drugs for Non-ST Segment Elevation Myocardial Infarction →

Sponsor

Seoul National University Hospital

Who can join

Eligibility, any sex, with Stable Angina or Unstable Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems still needs to be established.

Herein, we plan the HOST-coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial to compare single antiplatelet therapy (SAPT) after 3-month DAPT with 12-month DAPT in all-comers undergoing coronary intervention with third-generation DES with the thinnest struts.

P2Y12 inhibitor treatment is added to aspirin during the 3-months period after the stenting, and this abbreviated duration of DAPT will be compared with conventional 1-year mandatory DAPT regimen in a 1:1 randomized stratification.

Net adverse clinical events (NACEs), a composite of cardiac death, target vessel related myocardial infarction, clinically-drivent target lesion revascularization, definite or probable stent thrombosis and major bleeding is a primary endpoint for evaluating safety and efficacy of the difference of DAPT duration.

1-year target lesion failure (TLF) as a composite of cardiac death, target vessel related myocardial infarction and clinically driven target lesion revascularization will be identified as a secondary ischemic outcome. 1-year major bleeding events classified as BARC type 3 or 5 bleeding events will be identified as a secondary bleeding outcome.

With this trial, you will be able to get clear insight on the behavior of newer DES platforms. Reference data for the shortened mandatory DAPT regimen will also be delineated in the selected patients, and it might be helpful to those who need it.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
   Han JK, Hwang D, Yang S, Park SH, et al · · 2023 · cited 35× · PMID 36871230 · DOI 10.1161/circulationaha.123.064264
2. Comparison of Contemporary Drug-eluting Coronary Stents - Is Any Stent Better than the Others?
   Parker W, Iqbal J. · · 2020 · cited 12× · PMID 36277668 · DOI 10.17925/hi.2020.14.1.34
3. Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial.
   Kim CH, Han JK, Yang HM, Park KW, et al · · 2017 · cited 10× · PMID 29025834 · DOI 10.1136/bmjopen-2017-016617
4. The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.
   Han S, Suzuki-Kerr H, Vlajkovic SM, Thorne PR. · · 2022 · cited 9× · PMID 36173587 · DOI 10.1007/s11302-022-09896-w
5. Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
   Howard CE, Nambi V, Jneid H, Khalid U. · · 2019 · cited 9× · PMID 31576769 · DOI 10.1161/jaha.119.012639
6. Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial.
   Han JK, Lee K, Park SH, Yang S, et al · · 2025 · cited 6× · PMID 40160090 · DOI 10.1161/circinterventions.124.014623
7. Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial.
   Han JK, Yang S, Hwang D, Park SH, et al · · 2024 · cited 4× · PMID 38786579 · DOI 10.1161/circinterventions.123.013585
8. Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents in Complex Percutaneous Coronary Intervention: Post Hoc Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial.
   Park SH, Han JK, Yang S, Hwang D, et al · · 2026 · PMID 41717861 · DOI 10.1161/jaha.125.043441